|Chemohormonal therapy in metastatic hormone-sensitive prostate cancer|
CJ Sweeney, YH Chen, M Carducci, G Liu, DF Jarrard, M Eisenberger, ...
New England Journal of Medicine 373 (8), 737-746, 2015
|Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile|
J Hrkach, D Von Hoff, MM Ali, E Andrianova, J Auer, T Campbell, ...
Science translational medicine 4 (128), 128ra39-128ra39, 2012
|Enzalutamide with standard first-line therapy in metastatic prostate cancer|
ID Davis, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ...
New England Journal of Medicine 381 (2), 121-131, 2019
|Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial|
CE Kyriakopoulos, YH Chen, MA Carducci, G Liu, DF Jarrard, NM Hahn, ...
Journal of Clinical Oncology 36 (11), 1080, 2018
|Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017|
S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ...
European urology 73 (2), 178-211, 2018
|Redefining the target: chemotherapeutics as antiangiogenics|
KD Miller, CJ Sweeney, GW Sledge Jr
Journal of Clinical Oncology 19 (4), 1195-1206, 2001
|Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial|
DC Smith, MR Smith, C Sweeney, AA Elfiky, C Logothetis, PG Corn, ...
Journal of clinical oncology 31 (4), 412, 2013
|An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells|
ML Guzman, RM Rossi, S Neelakantan, X Li, CA Corbett, DC Hassane, ...
Blood, The Journal of the American Society of Hematology 110 (13), 4427-4435, 2007
|Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of …|
CL Vale, S Burdett, LHM Rydzewska, L Albiges, NW Clarke, D Fisher, ...
The lancet oncology 17 (2), 243-256, 2016
|Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study|
F Meric-Bernstam, H Hurwitz, KPS Raghav, RR McWilliams, M Fakih, ...
The Lancet Oncology 20 (4), 518-530, 2019
|The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but …|
CJ Sweeney, KD Miller, SE Sissons, S Nozaki, DK Heilman, J Shen, ...
Cancer research 61 (8), 3369-3372, 2001
|Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study|
JD Hainsworth, F Meric-Bernstam, C Swanton, H Hurwitz, DR Spigel, ...
Journal of Clinical Oncology 36 (6), 536-544, 2018
|Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation|
CL Hsieh, T Fei, Y Chen, T Li, Y Gao, X Wang, T Sun, CJ Sweeney, ...
Proceedings of the National Academy of Sciences 111 (20), 7319-7324, 2014
|Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015|
S Gillessen, A Omlin, G Attard, JS De Bono, E Efstathiou, K Fizazi, ...
Annals of Oncology 26 (8), 1589-1604, 2015
|Cyclooxygenase-2 expression in human pancreatic adenocarcinomas|
MT Yip-Schneider, DS Barnard, SD Billings, L Cheng, DK Heilman, A Lin, ...
Carcinogenesis 21 (2), 139-146, 2000
|Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer|
W Xie, MM Regan, M Buyse, S Halabi, PW Kantoff, O Sartor, H Soule, ...
Journal of Clinical Oncology 35 (27), 3097, 2017
|The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis|
A Pettersson, RE Graff, SR Bauer, MJ Pitt, RT Lis, EC Stack, NE Martin, ...
Cancer epidemiology, biomarkers & prevention 21 (9), 1497-1509, 2012
|Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis|
JH Hayes, DA Ollendorf, SD Pearson, MJ Barry, PW Kantoff, ST Stewart, ...
Jama 304 (21), 2373-2380, 2010
|Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group|
HL Kaufman, W Wang, J Manola, RS DiPaola, YJ Ko, C Sweeney, ...
Journal of Clinical Oncology 22 (11), 2122-2132, 2004
|Outcome of patients with a performance status of 2 in eastern cooperative oncology group study E1594: a phase III trial in patients with metastatic nonsmall cell lung carcinoma|
CJ Sweeney, J Zhu, AB Sandler, J Schiller, CP Belani, C Langer, J Krook, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2001